Griffith University researchers, in collaboration with the University of Queensland, have identified magnetic nanoparticles, nanozymes, which could help in the detection of cancer.

Researchers discovered the gold-loaded iron oxide nanozymes enhance the signal for cancer detection in breast cells by six-fold.

There are biomarkers or receptors expressed on the surface of healthy or cancer cells,” explained Dr Ian Cock from the Environmental Futures Research Institute.

“Cancer cells over-express these biomarkers on the surface of the cell.”

The goal is to measure this over-expression as accurately as possible by matching the biomarker lock with the right key.

The biosensing platform that the researcher developed is an array of keys that releases a signal when they come together with the biomarker locks on the cell.

“We quantify the electrical current produced from the chemical reactions when the biosensor platform recognises the markers on the cell surface,” Dr Cock said.

In this study the researchers assessed ways of modifying this interaction to increase the signal output in breast cancer cells, but not in unaffected ovarian cells.

“The signal output was enhanced by first binding nanomaterials loaded with locks to the cancer cells,” Dr Cock said.

“With more lock binding sites present, we increase the number of lock-key interactions for the biosensor platforms and so amplify the signal.

“We evaluated the performances of nanozyme by changing the biosensing platforms and substituting other biological variants for a complete cancer assay detection,” Dr Cock said.

The biosensing platform using magnetic nanoparticles containing gold-loaded iron oxide responded rapidly for a large range of cancer cell numbers.

The positive assay produced a six-fold increase in the signal output for the breast cancer cells compared to non-cancerous cell line.

ISSN: 2155-9899
Journal Impact Factor: 2.3*
NLM title abbreviation: J Clin Cell Immunol
NLM ID: 101563152
ICV: 82.55
DOI: 10.35248/2155-9899
Publication policy: Open Access
Contact email: immunology@eclinicalsci.com

JCCI is a prestigious peer-reviewed, open access journal publishing articles in the field of Immunology since 2010.

We are accepting the following types of manuscript: Research article, review articles, short note communications, case reports, Editorials, letters to the Editors and expert opinions & commentaries from different regions for publication.

All submitted material is subjected to a strict peer-review process. All correspondence, including notification of the Editor's decision (or) review comments and requests for revision, takes place by e-mail.

A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Authors can submit manuscripts online at Editorial Tracking System (https://www.longdom.org/submissions/clinical-cellular-immunology.html) or forwarded to the Editorial Office at: immunology@eclinicalsci.com

Benefits of Publication with us:

• Fast track Peer-review process in 21 days.
• Publication immediately after acceptance.
• Peer-review by international experts.
• Enhanced visibility for the published articles through digital media & Open-Access.

Media Contact:
Mercy Eleanor | Managing Editor
Journal of Clinical & Cellular Immunology
Whatsapp No:  +1-504-608-2390
Email: immunology@eclinicalsci.com